Clinical Core

临床核心总结 核心的首要目标是为大型临床研究提供研究诊断评估。 人群，特别强调对参与者进行纵向随访并跟踪至尸检， 为ADRC调查人员进行的研究项目提供特征良好的参与者， 合作者临床核心的重要重点-耶鲁ADRC广泛-包括细胞 神经科学，突触机制，并强调系统存储生物标本， 未来的生物标志物研究。神经影像学和液体生物标志物对AD诊断的重要性， 治疗的发展越来越受到重视，最近的研究强调了 根据β-淀粉样蛋白沉积、病理性tau蛋白和 神经变性（ATN）。耶鲁ADRC成像，生物标志物和神经病理学核心和特定 发展项目将寻求开发与AD和相关疾病相关的这些方法。在 与这些努力的伙伴关系，临床核心将承担广泛的成像研究的收集 和流体生物标志物标本在整个频谱的AD横截面和整个过程中， 纵向AD。目标1将通过招募250名新参与者来维持核心人群， AD的完整连续性（从临床前到痴呆）以及非AD痴呆和正常对照。目的2 将这些参与者纳入统一数据集（UDS）人群，并提供UDS测量结果 国家阿尔茨海默氏症协调中心（NACC）进行国家研究。目标3将入组受试者， 尸检程序。目标4将为ADRC附属的临床研究提供合适的受试者。目的 5将为耶鲁ADRC和其他研究人员收集生物标本进行生物标志物研究。Aim 6将提供帮助 研究教育的核心是培养未来的临床和翻译研究人员在AD和相关 紊乱这些目标将提供ADRC附属调查人员的准备能力，测试生物标记-一次 在AD发病机制的最早阶段的AD痴呆中得到验证。

SUMMARY OF THE CLINICAL CORE The over-arching goal of the Core will be to provide research diagnostic evaluations for a large clinical population with a special emphasis on participants who are followed longitudinally and tracked to autopsy to provide well-characterized participants for the research projects conducted by ADRC investigators and collaborators. Important focuses of the Clinical Core—as for the Yale ADRC broadly—include cellular neuroscience, synaptic mechanisms, and an emphasis on systematic storage of biospecimens for current and future biomarker studies. The importance of neuroimaging and fluid biomarkers for AD diagnosis and therapeutic development is increasing well appreciated, and recent research has emphasized the importance of classifying patients according to the presence of β-amyloid deposition, pathologic tau, and neurodegeneration (ATN). The Yale ADRC Imaging, Biomarker, and Neuropathology Cores and specific Developmental Projects will seek to develop these methods with relevance to AD and related disorders. In partnership with these efforts, the Clinical Core will undertake the collection of a wide range of imaging studies and fluid biomarker specimens across the full spectrum of AD cross-sectionally and during the full course of AD longitudinally. Aim 1 will maintain the Core Population through enrollment of 250 new participants on the full continuum of AD (from preclinical to dementia), as well as non-AD dementias and normal controls. Aim 2 will enroll these participants in the Uniform Data Set (UDS) population and make the UDS measures available to the National Alzheimer’s Coordinating Center (NACC) for national studies. Aim 3 will enroll subjects into the Autopsy Program. Aim 4 will provide appropriate subjects for the clinical studies affiliated with the ADRC. Aim 5 will collect biological specimens for Yale ADRC and other researchers for biomarker studies. Aim 6 will assist the Research Education Core in training future clinical and translational researchers in AD and related disorders. These Aims will provide ADRC affiliated investigators the ready ability to test biomarkers—once validated in AD dementia—in the earliest stages of AD pathogenesis.